PRECLINICAL EVALUATION OF A PATIENT-SPECIFIC NEOANTIGEN VACCINATION STRATEGY, AN IMPLANTABLE VACCINE DEVICE AND COMBINATORIAL REGIMENS TO ENHANCE ANTI-TUMOR IMMUNE RESPONSES.

PI: David A. Reardon, M.D.
Clinical Director, Center for Neuro-Oncology
Dana-Farber Cancer Institute

Close Menu